


PLM-101

| | |
|--------------------|-------------------------------------------------------------------------------------------|
| Cat. No.: | HY-149539 |
| Molecular Formula: | C ₂₂ H ₂₂ FN ₅ O ₂ |
| Molecular Weight: | 407.44 |
| Target: | FLT3; RET |
| Pathway: | Protein Tyrosine Kinase/RTK |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description | PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) ^[1] . |
| In Vitro | PLM-101 (30 nM, 100 nM) suppresses the phosphorylation of AKT (phospho-S473) and p70S6K (phospho-T389) in the PI3K signaling pathway, as well as the phosphorylation of MEK (phospho-S217/S221) and ERK (phospho-T202/Y204) in the Ras signaling pathway ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Choi YJ, et al. PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia. *Biomed Pharmacother.* 2023 Sep;165:115066..

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA